Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma

Technology appraisal guidance
Reference number: TA870
Published: 22 February 2023

History

Expected publication

Equality Impact Assessment (Guidance development) (PDF 145 KB)

Published:

22 February 2023

Final draft guidance

Final draft guidance
Committee papers (PDF 4.02 MB)

Published:

18 January 2023
Final appraisal document (PDF 246 KB)

Published:

18 January 2023
Public committee slides (PDF 1 MB)

Published:

18 January 2023

Invitation to participate

Final scope (PDF 215 KB)

Published:

10 March 2021
Final stakeholder list (PDF 405 KB)

Published:

10 March 2021

Draft guidance: TA505 ACD2

Committee papers (PDF 7.59 MB)

Published:

14 February 2023
Appraisal consultation document (PDF version) (PDF 503 KB)

Published:

14 February 2023

Draft guidance: TA505 ACD

Committee papers ACD 1 (PDF 40.03 MB)

Published:

14 February 2023
Appraisal consultation document (PDF version) (PDF 503 KB)

Published:

14 February 2023